Drugs / CD19-PD1-CART Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04163302 | Jul 2019 → Jul 2021 | lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-PD1-CART Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04163302 ↗ |
| Action | Deplete | “to specifically recognize and eliminate CD19-positive tumor cells” NCT04163302 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T (CART) cells” NCT04163302 ↗ |
| Route | Other | “CART cells were reinfused on the third day after the pretreatment.” NCT04163302 ↗ |
| Target | CD19 | “to specifically recognize and eliminate CD19-positive tumor cells” NCT04163302 ↗ |